

1	Type of Issue (PO / FPO)	IPO
---	--------------------------	-----

2	Issue Size (Rs. Cr)	500.0
	- Fresh Issue Size (Rs. Cr)	225.0
	- Offer for Sale Component (Rs. Cr)	275.0
	Source: Post Issue Monitoring Report	

3	Grade of issue along with name of the rating agency	Not Applicable
	Name	Not Applicable
	Grade	Not Applicable

4	Subscription Level (Number of times)	124.52*
	Source: Post Issue Monitoring Report	
	*The above figure is after technical rejections and includes anchor	

5	QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges	
	Particulars	%
	(i) allotment in the issue <sup>(1)</sup>	10.41%
	(ii) at the end of the 1st Quarter immediately after the listing of the issue	10.89%
	(iii) at the end of 1st FY (March 31, 2022)	11.19%
	(iv) at the end of 2nd FY (March 31, 2023)	15.25%
	(v) at the end of 3rd FY (March 31, 2024)	16.49%
	(1) Source: Minutes of Base of Allotment; Includes allotment to Anchor Investors	

6	Financials of the issuer			
		(In Rs. Crores)		
	Parameters (consolidated)	1st FY (March 31, 2022)	2nd FY (March 31, 2023)	3rd FY (March 31, 2024)
	Income from operations	433.65	423.61	393.50
	Net Profit for the period	95.87	46.49	30.35
	Paid-up equity share capital	22.17	22.17	23.30
	Reserves excluding revaluation reserves	450.92	492.62	713.69

7	Trading Status in the scrip of the issuer	
	Company's Equity Shares are listed on both the BSE Limited and the NSE. The Shares have not been suspended or delisted.	
	Particulars	Status
	(i) at the end of 1st FY (March 31, 2022)	Frequently traded
	(ii) at the end of 2nd FY (March 31, 2023)	Frequently traded
	(iii) at the end of 3rd FY (March 31, 2024)	Frequently traded
	Source: Stock exchange data	

8	Change in Directors of issuer from the disclosures in the offer document		
	Particulars	Name of the Director	Appointed / Resigned
	(i) at the end of 1st FY (March 31, 2022)	-	-
	(ii) at the end of 2nd FY (March 31, 2023)	-	-
	(iii) at the end of 3rd FY (March 31, 2024) <sup>a</sup>	-	-
	<sup>a</sup> Updated till May 31, 2024		
	* Changes in Directors not disclosed as the relevant fiscal year has not been completed.		

9	Status of implementation of project/ commencement of commercial production	
	(i) as disclosed in the offer document	Not applicable <sup>a</sup>
	(ii) Actual implementation	Not applicable <sup>a</sup>
	(iii) Reasons for delay in implementation, if any	Not applicable <sup>a</sup>
	*The Company did not undertake any project	

10	Status of utilization of issue proceeds					
	(i) as disclosed in the offer document					
		(In Rs. Crores)				
	Particulars	Total estimated amount/ expenditure	Amount already deployed as on June 30, 2021	Estimated utilisation from Net Proceeds	Estimated Deployment (Financial Year 2022)	Estimated Deployment (Financial Year 2023)
	Funding capital expenditure requirements for expansion of our Dahai Manufacturing Facility	151.32	4.22	147.10	79.00	68.10
	Funding capital expenditure requirements for upgradation at our R&D facility in Vadodara	23.97	0.00	23.97	13.00	10.97
	General corporate purposes	26.21	0.00	26.21	26.21	-
	<b>Total</b>	<b>201.50</b>	<b>4.22</b>	<b>207.28</b>	<b>128.21</b>	<b>79.07</b>
	Source: Sourced from Prospectus.					

(i)	Actual utilization	
		(In Rs. Crores)
	Particulars	As of March 31, 2023
	Funding capital expenditure requirements for expansion of our Dahai Manufacturing Facility	147.10
	Funding capital expenditure requirements for upgradation at our R&D facility in Vadodara	22.99
	General corporate purposes	26.21
	<b>Total</b>	<b>206.30</b>

\*Report issued by Monitoring agent dated May 3, 2024

Notes:

- Expansion of our Dahai Manufacturing Facility: The Company has completed expansion of its Dahai Manufacturing Facility at a cost of Rs. 1,529.35 million as against the original cost estimate as per offer document of Rs. 1,471.00 million. Increase in cost is on account of a variety of external factors such as market conditions, geopolitical situations, increasing inflation rates, the COVID-19 pandemic, competitive environment and interest rate or exchange rate fluctuations and other external factors which were beyond the control of management. The increased cost of Rs. 58.35 million has been funded from Internal Accruals. The Company has commenced commercial production on 05 April 2023. As at 31 December 2023, no amount is lying unspent with Monitoring Agency.
- Upgradation at our R&D facility in Vadodara: The delay in implementation is on account of a variety of external factors such as market conditions, the COVID-19 pandemic and other external factors, which were beyond the control of management. This reason may also entail rescheduling or revising the planned implementation schedule of Upgradation at our R&D facility in Vadodara, at the discretion of the management.

(ii)	Reasons for deviation, if any	Not available
------	-------------------------------	---------------

11	Comments of monitoring agency, if applicable	
	(a) Comments on use of funds	
	(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	None <sup>a</sup>
	(c) Any other reservations expressed by the monitoring agency about the end use of funds	
	*Report issued by Monitoring agent dated May 3, 2024	

12 Pricing Data

Issue Price (Rs.):	1083
Designated Stock Exchange:	BSE
Listing Date:	29-Jul-21

Price parameters	At close of listing day (Jul 29, 2021)	At close of 30th calendar day from listing day (Aug 27, 2021) <sup>(1)</sup>	At close of 90th calendar day from listing day (Oct 26, 2021) <sup>(2)</sup>	As at the end of 1st FY after the listing of the issue (March 31, 2022) <sup>(3)</sup>			As at the end of 2nd FY after the listing of the issue (March 31, 2023) <sup>(4)</sup>			As at the end of 3rd FY after the listing of the issue (March 31, 2024) <sup>(5)</sup>		
				Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange	2,134.25	2,085.60	2,546.60	2,327.70	2,975.55	2,020.75	1,656.90	2,649.10	1,606.00	1,119.50	1,887.95	1,061.35
Sector:	56,124.71	61,300.26	68,240.26	62,245.43	62,245.43	62,245.43	62,245.43	62,245.43	62,245.43	62,245.43	62,245.43	62,245.43
Sector Index <sup>(6)</sup>	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available

- Note:
- (1) 30th calendar day shall be taken as listing date plus 29 calendar days.
  - (2) 90th calendar day shall be taken as listing date plus 89 calendar days.
  - (3) High and Low based on intra day prices.
  - (4) Pricing data not disclosed as the relevant fiscal year has not completed.
  - (5) There is no sectoral index.

13 Basis for Issue Price

Accounting ratio	As disclosed in the offer document <sup>(1)</sup>	At the end of 1st FY (March 31, 2022)	At the end of 2nd FY (March 31, 2023)	At the end of 3rd FY (March 31, 2024)
<b>Issuer:</b>				
Basic	26.02	44.59	20.52	13.26
<b>Peer Group:</b>				
Aarti Industries Limited (Basic)	15.02	36.06	15.04	11.51
Navin Fluorine International Limited (Basic)	52.03	53.12	75.70	54.57
Akyl Amres Chemicals Limited (Basic)	57.87	44.04	44.75	29.13
Vitati Organics Limited (Basic)	26.20	33.73	33.72	31.20
Fine Organics Industries Limited (Basic)	39.25	54.71	192.63	134.34
<b>Industry Avg:</b>	Not Applicable	Not Applicable	Not Applicable	Not Applicable
<b>Issuer:</b>	41.62	51.75	81.23	84.46
<b>Peer Group:</b>				
Aarti Industries Limited	58.16	26.62	34.46	59.63
Navin Fluorine International Limited	73.12	76.85	56.34	57.37
Akyl Amres Chemicals Limited	64.04	64.94	48.21	65.30
Vitati Organics Limited	77.41	57.89	40.56	47.10
Fine Organics Industries Limited	75.01	47.39	22.36	31.34
<b>Industry Avg:</b>	69.55	54.72	40.39	52.15
<b>Issuer:</b>	31.49	20.27	8.83	4.12%
<b>Peer Group:</b>				
Aarti Industries Limited	15.23	22.10	10.06	7.88%
Navin Fluorine International Limited	15.76	14.27	17.17	11.35%
Akyl Amres Chemicals Limited	37.27	22.72	19.56	11.75%
Vitati Organics Limited	17.45	18.96	25.03	13.12%
Fine Organics Industries Limited	16.45	27.07	38.84	21.44%
<b>Industry Avg:</b>	Not Applicable	Not Applicable	Not Applicable	Not Applicable
<b>Issuer:</b>	82.62	213.44	232.25	315.10
<b>Peer Group:</b>				
Aarti Industries Limited	48.48	163.16	135.73	145.98
Navin Fluorine International Limited	33.01	372.17	440.93	480.63
Akyl Amres Chemicals Limited	15.53	193.80	229.87	247.87
Vitati Organics Limited	15.02	177.85	177.85	237.73
Fine Organics Industries Limited	23.86	312.85	496.46	626.67
<b>Industry Avg:</b>	Not Applicable	Not Applicable	Not Applicable	Not Applicable

- Notes:**
- (1) Sourced from Prospectus.
  - (2) Information not provided as the relevant fiscal year has not completed.
  - (3) Key ratios for the Company for 1st FY and 2nd FY stated above are calculated as follows:
    - (i) Basic and diluted earnings per Equity Share are based on the Annual Reports for the relevant years.
    - (ii) P/E - Closing Market Price on BSE as of relevant fiscal year / EPS (diluted). Also disclosed EPS (Basic) for the Issuer.
    - (iii) RoNW - Net profit after tax attributable to the owners divided by net worth at the end of the relevant period.
    - (iv) NAV per share - Net worth at the end of the relevant period divided by Total Equity Shares Outstanding as of fiscal year end.

14 Any other material information

Date of disclosure to Designated Stock Exchange	Announcement
6-Aug-21	Tatva Chemie Pharma Chem Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2021, inter alia, to consider and approve: 1. the unaudited Standalone financial results of the Company for the quarter ended 30 June 2021 and 2. the unaudited Consolidated financial results of the Company for the quarter ended 30 June 2021.
14-Aug-21	1. Copy of the Limited Review Report of the Statutory Auditors of the Company, M/s. NDJ & Co, Chartered Accountants, (Firm Registration No. 136345W), on the Un-audited Consolidated Financial Results. 2. Copy of the Un-audited Consolidated Financial Results of the Company for the quarter ended 30th June, 2021 of the Current Financial Year 2021-22. 3. Copy of the Limited Review Report of the Statutory Auditors of the Company, M/s. NDJ & Co, Chartered Accountants, (Firm Registration No. 136345W), on the Un-audited Standalone Financial Results. 4. Copy of the Un-audited Standalone Financial Results of the Company for the quarter ended 30th June, 2021 of the Current Financial Year 2021-22.
14-Aug-21	Intimation under Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 submitted.
16-Aug-21	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed a copy of the Press Release on the financial results of the Company for the quarter ended 30 June 2021.
16-Aug-21	Pursuant to regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we enclosed herewith copies newspaper publication of extract of unaudited financial results of the Company for the quarter ended on 30 June 2021, published in Financial Express (English edition) and Vadodra Samachar (Gujarati edition) on 15 August 2021.
24-Aug-21	Pursuant to Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation 2015, we hereby inform that Mr. Mahesh Tanna, Chief Financial Officer (CFO) of the Company has tendered his resignation from the post of Chief Financial Officer and Key Managerial Personnel (KMP) of the Company on 24th August, 2021. The Company has accepted his resignation and he will be relieved from the Company on 31st August, 2021 after closure of working hours.
1-Sep-21	The transcript of the earnings call held on 16 August 2021 post announcement of financial results of the company for the quarter ended 30 June 2021.
6-Sep-21	Pursuant to Regulation 47 and Regulation 30 read with Schedule III Part A Para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find enclosed herewith the copies of newspaper advertisement published in English Language Newspaper published in Financial Express and in Vernacular Newspaper in Vernacular Language Vadodra Samachar, on 08th September, 2021, in compliance with the Ministry of Corporate Affairs Circular No. 20/2020 dated 5 May 2020, intimating that the 25th Annual General Meeting (AGM) of members of the Company will be held on Wednesday, 29th September, 2021 at 4:00 p.m. (IST) through Video Conferencing (VC) / Other Audio Visual Means (OAVM) and information on related matters as required under the said MCA Circular.
6-Sep-21	Pursuant to Regulation 34(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We hereby enclosed the 25th Annual Report along with the Notice calling 25th Annual General Meeting of the Company scheduled to be held on Wednesday, 29 September, 2021 at 4:00 p.m. (IST) through Video Conferencing (VC) / Other Audio Visual Means (OAVM) (Comprising of Audited Standalone and Consolidated Financial Statements, Directors Report etc.) which is sent through electronic mode to the Members pursuant to the MCA Circular No. 20/2020 dated 5 May, 2020 read with Circular Nos. 14/2020 dated 8 April, 2020, 17/2020 dated 13 April, 2020 and 02/2021 dated 13 January, 2021 and SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated 12 May, 2020 and Circular No. SEBI/HO/CFD/CMD2/CIR/P/2021/11 dated 15 January, 2021 for the financial year ended 31 March, 2021.
6-Sep-21	Pursuant to Regulation 30 read with clause 12 of Part A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, We wish to inform you that the 25th Annual General Meeting (AGM) of the members of the Company will be held on Wednesday, 29 September, 2021, at 4:00 P.M. (IST) through Video Conferencing (VC) / Other Audio Visual Means (OAVM). Pursuant to provisions of Section 108 of the Companies Act 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended and Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations) the Company is providing to its members the facility to cast their vote by electronic means on all the resolutions set forth in the Notice.
23-Oct-21	We wish to inform that the Board of Directors of the Company at its meeting held today i.e., 23 October 2021, has approved the unaudited financial results of the Company (both standalone and consolidated) prepared in accordance with Indian Accounting Standards (IndAS) for the quarter and half year ended as on 30 September 2021. A copy of the said Financial Results together with Limited review report are enclosed herewith. The Board meeting commenced at 11.30 am and concluded at 3.00 pm.

23-Oct-21	Pursuant to Regulation 30(5) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, We are hereby disclosing the updated contact details of Key Managerial Personnel (KMP) who has been authorized by the Board of Directors at their meeting held on 23 October 2021 of the Company for the purpose of determining materiality of an event or information and of making disclosure of such material information to the stock exchange under these regulations as stated below: Sr.No Name of KMP Designation Contact Details 01. Mr Ajay Mansushil Patil/Whole time Director Email:ajay@tatvachintan.com Contact no:+91 75748 48533 / 34 02 Mr. Chetan Nitinram Shah/Managing Director Email:chetan@tatvachintan.com Contact no:+91 75748 48533 / 34 Kindly take the above disclosure on your records.
25-Oct-21	Pursuant to regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we are enclosing herewith copies newspaper publication of extract of unaudited financial results of the Company for the quarter ended on 30 September 2021, published in Financial Express (English edition) and Vadodara Samachar (Gujarati edition) on 24 October 2021. Kindly take the same on record and disseminate to the public at large
27-Oct-21	Pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith statement of deviation(s) or variations in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended 30 September 2021 in the prescribed format. The same will be filed in XBRL mode separately. We confirm that, as at 30 September 2021, there has not been any deviation(s) or variation(s) in the utilization of net proceeds of IPO as mentioned in the objects stated in the Prospectus dated 22 July 2021. Monitoring agency report issued in this regard is being separately filed with the exchange.
28-Oct-21	Pursuant to Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Monitoring agency report of the Company for the quarter ended 30 September 2021, issued by ICICI Bank Limited, appointed to monitor the utilization of proceeds of an Initial Public Offering (IPO) of the Company. Request you to please take the above on record.
29-Oct-21	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on 25 October 2021 post announcement of financial results of the Company for the quarter and half year ended 30 September 2021. The Transcript has been uploaded on the Company's website www.tatvachintan.com. This is for your information and records.
29-Oct-21	Please find enclosed herewith, INVESTOR DECK which contain general and financial information about the company. This information is being submitted for general purpose only and not under any statutory requirements. Kindly take note of the same. The same will also be available on the Company's website, "www.tatvachintan.com". This is for your information and records.
29-Nov-21	With reference to the above subject, we would like to inform you that as a part of future need, the Company has acquired an industrial land measuring 50,359.16 Sq. mtr at Dahajig GIDC Estate, Bharuch, Gujarat, India. The above land has been acquired from internal accruals only & will be used on need basis in future. The above disclosure is being made voluntarily for the record of Stock Exchanges. Kindly take the above disclosure on your records.
3-Dec-21	Pursuant to Regulation 30 of the SEBI (LDR) Regulations, 2015 as amended, we wish to inform that based on recommendation of the Nomination and Remuneration Committee (NRC), the Board of Director of the Company at its meeting held on Friday, 03 December 2021, has appointed Mr. Anshu Borra (Chartered Accountant) as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the Company with effect from 03 December 2021. The disclosure required under Regulation 30 of SEBI (LDR) Regulations, 2015 read with para A of Part A of Schedule III of the said regulations and read with SEBI Circular No. CIR-CPD/CMD/42015 dated 09 September 2015 is enclosed in Annexure-1
5-Jan-22	Complies Certificate under Reg. 74 (6) of SEBI (DPI) Regulations, 2018
7-Jan-22	Tatva Chintan Pharma Chem Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/01/2022, inter alia, to consider and approve Pursuant to the Regulation 29 (1) (a) read with Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we hereby inform you that the Meeting of the Board of Directors of Tatva Chintan Pharma Chem Limited is scheduled to be held on Monday, 17 January, 2022, inter alia to: 1. Consider and approve the unaudited standalone financial results of the Company for the quarter/ nine months ended 31 December, 2021. 2. Consider and approve the unaudited consolidated financial results of the Company for the quarter/ nine months ended 31 December 2021. Kindly take the above information on your record.
11-Jan-22	Statement Of Investor Complaints For The Quarter Ended December 2021 submitted
13-Jan-22	The Company had moved Adjudication Application before the office of ROC on suo-moto basis in April 2021. In the said Adjudication Application, We have received an order from the office of ROC with a penalty on the Company, its three directors and two key managerial personnel. The details of the same are: During RHP IPO, Company has found that it has not complied with the section 42 of the Companies Act, 2013 w.r.t. opening of separate bank account for depositing the share application money in the year 2015. Accordingly, the same was disclosed in RHP (Refer point no. 28 on Pg. No. 36 and 37). Adjudication Application was submitted on suo-moto basis before the office of ROC in April 2021. Company being an aggrieved party, has decided to appeal against the said order before office of Regional Director, NWR, MCA
17-Jan-22	Outcome of the Board Meeting held on January 17, 2022 submitted
17-Jan-22	Pursuant to the provisions of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Ms. Aparna Dubey has tendered her resignation today i.e. January 17, 2022 from the post of Company Secretary and Compliance Officer (Key Managerial Personnel) of Tatva Chintan Pharma Chem Limited. She will continue to work with Tatva Chintan Pharma Chem Limited as Assistant Company Secretary of the Company. The Company has accepted her resignation and she shall cease to be the Company Secretary and Compliance Officer (Key Managerial Personnel) with effect from close of working hours of January 17, 2022. However, she will continue to work with Tatva Chintan Pharma Chem Limited as mentioned above. We request you to kindly take the above on record and oblige
17-Jan-22	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Press Release on the financial results of the Company for the quarter and nine months ended December 31, 2021.
18-Jan-22	Pursuant to regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we are enclosing herewith copies newspaper publication of extract of unaudited financial results of the Company for the quarter and nine months ended on December 31, 2021, published in Financial Express (English edition) and Vadodara Samachar (Gujarati edition) on January 18, 2022. Kindly take the same on record and disseminate to the public at large.
18-Jan-22	We hereby enclosed Investor Presentation for the quarter and nine months ended December 31, 2021. The same will be uploaded on the Company's website.
20-Jan-22	Pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith statement of deviation(s) or variations in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended December 31, 2021 in the prescribed format. The same will be filed in XBRL mode separately. We confirm that, as at December 31, 2021, there has not been any deviation(s) or variation(s) in the utilization of net proceeds of IPO as mentioned in the objects stated in the Prospectus dated July 22, 2021. Monitoring agency report issued in this regard is being separately filed with the exchange. Kindly take the above information on your record.
20-Jan-22	Pursuant to Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Monitoring agency report of the Company for the quarter ended December 31, 2021, issued by ICICI Bank Limited, appointed to monitor the utilization of proceeds of an Initial Public Offering (IPO) of the Company. Kindly take the above information on your record.
21-Jan-22	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on January 18, 2022 post announcement of financial results of the Company for the quarter and nine months ended December 31, 2021. The same will be uploaded on the Company's website. This is for your information and records.
24-Jan-22	With reference to above mentioned subject, we would like to inform you that there is typographical error in point no. 6 of notes to Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended on December 31, 2021. The respective correction does not have any impact on financial figure results/XBRL.
1-Feb-22	Pursuant to Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we would like to inform you that we have revamped our website i.e. www.tatvachintan.com, which is more user and investor friendly. Request you to please take the above on record.
30-Mar-22	Pursuant to provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended and Company's code on prohibition of insider trading, the Trading Window for dealing in the securities of the Company shall remain closed for all Designated Persons and their immediate relatives from Friday, 01 April 2022 till the completion of 48 hours after the Audited Financial Results of the Company for the Fourth Quarter and Financial Year ending 31 March 2022 become Generally Available Information. Accordingly, all Designated Persons and their immediate relatives of the Company have been advised not to trade in the securities of the Company during the aforesaid period of Closure of Trading Window. Kindly take the above information on your record.
6-Apr-22	Compliance Certificate pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018
7-Apr-22	Statement Of Investor Complaints For The Quarter Ended March 2022
7-Apr-22	Compliance certificate pursuant to Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the year ended 31 March 2022.
9-Apr-22	Pursuant to Regulation 40(9) & (10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Certificate obtained from M/s. TNT & Associates, Practicing Company Secretaries for the year ended on 31 March 2022. Kindly take the above information on your record.
15-Apr-22	Tatva Chintan Pharma Chem Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/04/2022, inter alia, to consider and approve 1. consider and approve and take on record the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31 March 2022; 2. consider and recommend a final dividend, if any, on the equity shares of the Company for the financial year ended 31 March 2022, subject to approval of the shareholders at the ensuing Annual General Meeting of the Company. Further, in accordance with the Company's Code of Conduct for Prohibition of Insider Trading, the Company has intimated its "designated persons" regarding the closure of the Trading Window for trading in the Company's equity shares from 01 April 2022 till the expiry of 48 hours from the date the said financial results are made public. The above information is also being made available on the website of the Company at www.tatvachintan.com. Kindly take above intimation on your record and oblige.
16-Apr-22	Tatva Chintan Pharma Chem Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on April 25, 2022, inter alia, to: 1. consider and approve and take on record the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended March 31, 2022; 2. consider and recommend a final dividend, if any, on the equity shares of the Company for the financial year ended March 31, 2022, subject to approval of the shareholders at the ensuing Annual General Meeting of the Company. Further, in accordance with the Company's Code of Conduct for Prohibition of Insider Trading, the Company has intimated its "designated persons" regarding the closure of the Trading Window for trading in the Company's equity shares from April 01, 2022 till the expiry of 48 hours from the date the said financial results are made public.
20-Apr-22	Format of Initial Disclosure to be made by an entity identified as a Large Corporate submitted
25-Apr-22	Outcome Of The Board Meeting Held On 25.04.2022 submitted
25-Apr-22	Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended on 31 March 2022
25-Apr-22	The Board Recommended a Final Dividend of Rs. 2/- (20%) per equity share of Rs. 10/- each fully paid (subject to deduction of tax, if any) on the equity share capital of Rs. 22,16,50,620/- (2,21,65,06,200 equity shares of Rs. 10/- each) for the financial year 2021-22. This shall be paid subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company.

25-Apr-22	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Press Release on financial results of the Company for the quarter and year ended 31 March 2022. The above information is also being made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . This is for your information and records.
25-Apr-22	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed Investor Presentation for the quarter and year ended 31 March 2022. The above information is also being made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . This is for your information and records.
25-Apr-22	Pursuant to Regulation 46(2)(iii) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform the exchanges that the recording of the Earnings Call held on Monday, 25 April 2022 at 5:00 pm IST is available on the website of the Company. The recording can be accessed from the following link: <a href="https://www.tatvachintan.com/wp-content/uploads/2022/04/Audio-Link.mp3">https://www.tatvachintan.com/wp-content/uploads/2022/04/Audio-Link.mp3</a>
26-Apr-22	Pursuant to regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find enclosed herewith copies of newspaper advertisement pertaining to extract of financial results of the Company for the quarter and year ended 31 March 2022, published in Financial Express (English edition) and Vadodra Samachar (Gujarati edition) on 26 April 2022. The above information will also be hosted on Company's website at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . Kindly take the same on record and disseminate to the public at large.
28-Apr-22	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on 25 April 2022 post announcement of financial results of the Company for the quarter and year ended 31 March 2022. The above information will also be hosted on Company's website at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . This is for your information and records.
30-Apr-22	Pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith statement of deviation(s) or variation(s) in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended 31 March 2022 in the prescribed format. The same will be filed in XBRL mode separately. We confirm that, as at 31 March 2022, there has not been any deviation(s) or variation(s) in the utilization of net proceeds of IPO as mentioned in the objects stated in the Prospectus dated 22 July 2021. Report issued by Monitoring agency report is being separately filed with the exchange. The above information is also being made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . Kindly take the above information on your record.
30-Apr-22	Pursuant to Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Monitoring agency report of the Company for the quarter ended 31 March 2022, issued by ICICI Bank Limited, appointed to monitor the utilization of proceeds of an Initial Public Offering (IPO) of the Company. The above information is also being made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . Kindly take the above information on your record.
4-May-22	Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular no. CIR/CFD/CMD/127/2019 dated February 8, 2019, please find enclosed herewith copy of the Annual Secretarial Compliance Report of the Company issued by M/s. TNT & Associates, Practising Company Secretaries, Vadodra, Gujarat, India for the financial year ended 31 March 2022. The above information shall be placed on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . Kindly take the above information on your record.
11-May-22	Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
20-May-22	Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions for the half year ended 31 March 2022. The above information shall be uploaded on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . Kindly take the same on your record.
6-Jul-22	Pursuant to Regulation 30 read with Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Regulations") as amended, in accordance with the said Regulation, we wish to inform that CRISIL Ratings Limited has Reaffirmed the credit ratings of the Company as under: Facilities Rating Remains Long Term Rating CRISIL A- (Stable) No change Short Term Rating CRISIL A2- No change. The above information shall be updated on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . You are requested to kindly take the same on record.
6-Jul-22	Compliance Certificate pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018
8-Jul-22	Intimation under Regulation 30 read with Point No. 8, Para B of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
8-Jul-22	Statement of Investor Complaints For The Quarter Ended June 2022
15-Jul-22	Tata Chintan Pharma Chem Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/07/2022, inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we hereby inform you that a meeting of the Board of Directors of Tata Chintan Pharma Chem Limited is scheduled to be held on Monday, 25 July 2022, inter alia, to consider, approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30 June 2022. Further, in accordance with the Company's Code of Procedure for Issuer Trading, the Company has intimated its "designated persons" regarding the closure of the Trading Window for trading in the Company's equity shares from 01 July 2022 till the expiry of 48 hours from the date the said financial results are made public. The above information is also being made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . Kindly take above intimation on your record and oblige.
	Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Listing Regulations), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30 June 2022.
	The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 25 July 2022.
25-Jul-22	Further, we enclose herewith Limited Review Report issued by M/s. NDU & Co., Chartered Accountants, (Firm Registration No. 136349W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations.
	The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> .
	The Board meeting commenced at 11:30 A.M. and concluded at 03:30 P.M.
	Kindly take above intimation on your record and oblige.
25-Jul-22	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed Investor Presentation for the quarter ended 30 June 2022. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . This is for your information and records.
25-Jul-22	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Press Release on financial results of the Company for the quarter ended 30 June 2022. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . This is for your information and records.
25-Jul-22	Pursuant to Regulation 46(2)(iii) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we hereby inform the exchanges that the recording of the Earnings Call held on Monday, 25 July 2022 at 05:00 pm IST is available on the website of the Company. The recording can be accessed from the following link: <a href="https://www.tatvachintan.com/wp-content/uploads/2022/07/Recording-2022-23-01.mp3">https://www.tatvachintan.com/wp-content/uploads/2022/07/Recording-2022-23-01.mp3</a> The above information is available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . Kindly take above intimation on your record and oblige.
26-Jul-22	Pursuant to regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we are enclosing herewith copies of newspaper publication of extract of financial results of the Company for the quarter ended 30 June 2022, published in Financial Express (English edition) and Vadodra Samachar (Gujarati edition) on 26 July 2022. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . Kindly take the same on record and disseminate to the public at large.
29-Jul-22	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on 25 July 2022 post announcement of financial results of the Company for the quarter ended 30 June 2022. The above information shall be made available on Company's website at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . This is for your information and records.
6-Aug-22	Pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith statement of deviation(s) or variation(s) in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended 30 June 2022 in the prescribed format. The same will be filed in XBRL mode separately. We confirm that, as at 30 June 2022, there has not been any deviation(s) or variation(s) in the utilization of net proceeds of IPO as mentioned in the objects stated in the Prospectus dated 22 July 2021. Report issued by Monitoring agency report is being separately filed with the exchange. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . Kindly take the above information on your record.
6-Aug-22	Pursuant to Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Monitoring agency report of the Company for the quarter ended 30 June 2022, issued by ICICI Bank Limited, appointed to monitor the utilization of proceeds of an Initial Public Offering (IPO) of the Company. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . Kindly take the above information on your record.
9-Aug-22	Pursuant to the changes introduced by the Finance Act, 2020, Dividend Distribution Tax has been abolished with effect from 01 April 2020 and the Dividend Income is taxable in the hands of the Shareholders. In this regard, please find enclosed herewith an email communication which has been sent to all the shareholders having their email ID's registered with the Company's Registrar & Transfer Agent/ Depositories explaining the process and documentation required for claiming tax exemption/holding tax on dividend to the Shareholders at prescribed rates. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . You are requested to take the same on your records.
17-Aug-22	Pursuant to Regulation 30 read with Schedule I Part A Para A and Regulation 47 of the SEBI Listing Regulations and in compliance with the General Circulars dated 18 April 2020, 13 April 2020, 05 May 2020, 13 January 2021, 14 December 2021 and 05 May 2022 issued by Ministry of Corporate Affairs, please find enclosed herewith the copies of newspaper advertisement published in Financial Express (in English Language) and Vadodra Samachar (in Gujarati Language) on 17 August 2022, intimating that the 26th Annual General Meeting (AGM) of the Company will be held on Thursday, 22 September 2022 at 04:00 p.m. (IST) through Video Conferencing (VC) / Other Audio Visual Means (OAVM). The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . Kindly take the above information on record.
23-Aug-22	Pursuant to Regulation 30 of the SEBI Listing Regulations, please find enclosed herewith Notice of the 26th AGM of the Members of the Company scheduled to be held on Thursday, 22 September 2022 at 04:00 p.m. (IST) through Video Conferencing (VC) / Other Audio Visual Means (OAVM). The Notice of the 26th AGM of the Company is also available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . Kindly take the above information on record.
23-Aug-22	Pursuant to Regulation 34(1) of the SEBI Listing Regulations, please find enclosed herewith Annual Report of the Company along with the Notice of the 26th Annual General Meeting (AGM) and other Statutory Reports for the Financial Year 2021-22. The same is also being sent through electronic mode to those Members whose email addresses are registered with the Company/Registrar and Share Transfer Agent/Depository Participants. Further, the 26th AGM of the Members of the Company will be held on Thursday, 22 September 2022 at 04:00 p.m. (IST) through Video Conferencing (VC) / Other Audio Visual Means (OAVM). The Annual Report of the Company is also available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . Kindly take the above information on record.
23-Aug-22	Intimation of Record date, Book Closure and Cut-off date pursuant to Regulation 42 and 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)
24-Aug-22	Pursuant to Regulation 30 read with Schedule I Part A Para A, Regulation 44 and Regulation 47 of the SEBI Listing Regulations and in compliance with Section 166 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended and the Secretarial Standards on General Meetings issued by the Institute of Company Secretaries of India, please find enclosed herewith the copies of newspaper advertisement published in Financial Express (in English Language) and Vadodra Samachar (in Gujarati Language) on 24 August 2022 for giving Notice of the 26th Annual General Meeting of the Company scheduled to be held on Thursday, 22 September 2022 at 04:00 p.m. (IST) through Video Conferencing (VC) / Other Audio Visual Means (OAVM) containing Record date, Book closure and remote e-voting details. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . Kindly take the above information on record.
25-Aug-22	Submission of Revised Annual Report of the Company for the Financial Year 2021-22 under Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)
22-Sep-22	Pursuant to provisions of Regulation 30 read with Part A of Schedule III and all other applicable regulations, if any, of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, please find enclosed herewith Proceedings of the 26th Annual General Meeting (AGM) of the Members of Tata Chintan Pharma Chem Limited (the Company) held on Thursday, 22 September 2022 at 04:00 p.m. (IST), through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The proceedings of 26th Annual General Meeting of the Company shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> .
23-Sep-22	Pursuant to Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, please find enclosed the voting results of the business transacted at the 26th Annual General Meeting (AGM) of the members of the Company held on Thursday, 22 September 2022 at 04:00 p.m. (IST) through Video Conferencing (VC) / Other Audio Visual Means (OAVM). We are also enclosing herewith the Consolidated Report of the scrutinizer on the remote e-voting and e-voting held during the course of AGM. The above are also being uploaded at the Company's website at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> and on the website of Link Intime India Private Limited, an agency appointed for the purpose of conducting the remote e-voting and e-voting during the process of AGM.
29-Sep-22	Pursuant to provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended and Company's code on prohibition of insider trading, the "Trading Window" for dealing in the securities of the Company shall remain closed for all Designated Persons and their immediate relatives from Saturday, 01 October 2022 till the completion of 48 hours after the Unaudited Financial Results of the Company for the quarter and half year ending 30 September 2022 become Generally Available Information. Accordingly, all Designated Persons and their immediate relatives of the Company have been advised not to trade in the securities of the Company during the aforesaid period of Closure of Trading Window.
6-Oct-22	Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please find enclosed Compliance Certificate for the quarter ended 30 September 2022, received from M/s Link Intime India Private Limited, our Registrar and Share Transfer Agent. The above information shall be uploaded on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> .

20-Oct-22	Tata Chintan Pharma Chem Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2022. Inter alia, to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30 September 2022. Further, in accordance with the Company's Code of Conduct for Prohibition of Insider Trading, the Company has intimated its "designated persons" regarding the closure of the Trading Window for trading in the Company's equity shares from 01 October 2022 till the expiry of 48 hours from the date the said financial results are made public. The above information is also being made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . Kindly take above information on your record and oblige.
4-Nov-22	Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Listing Regulations), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30 September 2022. The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 04 November 2022. Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . The Board meeting commenced at 01:00 P.M. and concluded at 03:55 P.M.
4-Nov-22	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed Investor Presentation for the quarter and half year ended 30 September 2022. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> .
4-Nov-22	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Press Release on financial results of the Company for the quarter and half year ended 30 September 2022. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> .
4-Nov-22	Pursuant to Regulation 46(2)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we hereby inform the exchanges that the recording of the Earnings Call held on Friday, 04 November 2022 at 05:00 p.m. IST is available on the website of the Company. The recording can be accessed from the following link: <a href="https://www.tatvachintan.com/wp-content/uploads/2022/11/ICICI430221104143915.mp3">https://www.tatvachintan.com/wp-content/uploads/2022/11/ICICI430221104143915.mp3</a> The above information is available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> .
5-Nov-22	Pursuant to regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we are enclosing herewith copies of newspaper publication of extract of financial results of the Company for the quarter and half year ended 30 September 2022, published in Financial Express (English edition) and Validara Samachar (Gujarati edition) on 05 November 2022. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> .
8-Nov-22	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on 04 November 2022 post announcement of financial results of the Company for the quarter and half year ended 30 September 2022. The above information shall be made available on Company's website at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> .
10-Nov-22	Pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith statement of deviation(s) or variation(s) in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended 30 September 2022 in the prescribed format. The same will be filed in XBRL mode separately. We confirm that, as on 30 September 2022, there has not been any deviation(s) or variation(s) in the utilization of net proceeds of IPO as mentioned in the objects stated in the Prospectus dated 22 July 2021. Report issued by Monitoring agency report is being separately filed with the exchange. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> .
10-Nov-22	Pursuant to Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Monitoring agency report of the Company for the quarter ended 30 September 2022, issued by ICICI Bank Limited, appointed to monitor the utilization of proceeds of an Initial Public Offering (IPO) of the Company. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> .
16-Nov-22	In terms of Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose disclosure of Related Party Transactions in the format specified under SEBI Circular bearing reference No. SEBI/HO/CFD/CMP/ICR/P02/1662 dated 22 November 2021, for the half year ended 30 September 2022. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> .
29-Dec-22	Pursuant to provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended and Company's code on prohibition of insider trading, the Trading Window for dealing in the securities of the Company shall remain closed for all Designated Persons and their immediate relatives from Sunday, 01 January 2023 till the completion of 48 hours after the Unaudited Financial Results of the Company for the quarter and nine months ending 31 December 2022 become Generally Available Information. Accordingly, all Designated Persons and their immediate relatives of the Company have been advised not to trade in the securities of the Company during the aforesaid period of Closure of Trading Window.
7-Jan-23	Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please find enclosed Compliance Certificate for the quarter ended 31 December 2022, received from M/s Link Intime India Private Limited, our Registrar and Share Transfer Agent. The above information shall be uploaded on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> .
13-Jan-23	Tata Chintan Pharma Chem Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2023. Inter alia, to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2022. Further, in accordance with the Company's Code of Conduct for Prohibition of Insider Trading, the Company has intimated its "designated persons" regarding the closure of the Trading Window for trading in the Company's equity shares from 01 January 2023 till the expiry of 48 hours from the date the said financial results are made public. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> .
24-Jan-23	Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Listing Regulations), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2022. The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 24 January 2023. Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . The Board meeting commenced at 12:30 P.M. and concluded at 03:35 P.M.
24-Jan-23	Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Listing Regulations), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2022. The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 24 January 2023. Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . The Board meeting commenced at 12:30 P.M. and concluded at 03:35 P.M.
24-Jan-23	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed Investor Presentation for the quarter and nine months ended 31 December 2022. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> .
24-Jan-23	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Press Release on financial results of the Company for the quarter and nine months ended 31 December 2022. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> .
24-Jan-23	Pursuant to Regulation 46(2)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we hereby inform the exchanges that the recording of the Earnings Call held on Tuesday, 24 January 2023 at 05:00 p.m. IST is available on the website of the Company. The recording can be accessed from the following link: <a href="https://www.tatvachintan.com/wp-content/uploads/2023/01/ICICI430230124144995.mp3">https://www.tatvachintan.com/wp-content/uploads/2023/01/ICICI430230124144995.mp3</a> The above information is available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> .
25-Jan-23	Pursuant to regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we are enclosing herewith copies of newspaper publication of extract of financial results of the Company for the quarter and nine months ended 31 December 2022, published in Financial Express (English edition) and Validara Samachar (Gujarati edition) on 25 January 2023. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> .
30-Jan-23	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on 24 January 2023 post announcement of financial results of the Company for the quarter and nine months ended 31 December 2022. The above information shall be made available on Company's website at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> .
1-Feb-23	Pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith statement of deviation(s) or variation(s) in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended 31 December 2022 in the prescribed format. The same will be filed in XBRL mode separately. We confirm that, as at 31 December 2022, there has not been any deviation(s) or variation(s) in the utilization of net proceeds of IPO as mentioned in the objects stated in the Prospectus dated 22 July 2021. Report issued by Monitoring agency report is being separately filed with the exchange. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> .
1-Feb-23	Pursuant to Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Monitoring agency report of the Company for the quarter ended 31 December 2022, issued by ICICI Bank Limited, appointed to monitor the utilization of proceeds of an Initial Public Offering (IPO) of the Company. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> .
30-Mar-23	Pursuant to provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended and Company's code on prohibition of insider trading, the Trading Window for dealing in the securities of the Company shall remain closed for all Designated Persons and their immediate relatives from Saturday, 01 April 2023 till the completion of 48 hours after the Unaudited Financial Results of the Company for the quarter and financial year ending 31 March 2023 become Generally Available Information. Accordingly, all Designated Persons and their immediate relatives of the Company have been advised not to trade in the securities of the Company during the aforesaid period of Closure of Trading Window.
5-Apr-23	Pursuant to Regulation 30 read with Para B of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we are pleased to inform you that the Company has successfully commenced its commercial production from New Facility at our Dabhi Manufacturing plant situated at Plot No. 2/103/F/162, SEZ Area, Pan-2, Dabhi, Bharuch, Gujarat - 392130 on 05 April 2023. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> .
7-Apr-23	Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please find enclosed Compliance Certificate for the quarter ended 31 March 2023, received from M/s Link Intime India Private Limited, our Registrar and Share Transfer Agent.
11-Apr-23	Compliance certificate pursuant to Regulation 7(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the year ended 31 March 2023.
12-Apr-23	Pursuant to Regulation 40(9) & (10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Certificate obtained from M/s. TNT & Associates, Practicing Company Secretaries for the year ended on 31 March 2023.
25-Apr-23	Tata Chintan Pharma Chem Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/05/2023. Inter alia, to consider and approve 1. consider and approve and take on record the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31 March 2023; 2. consider and recommend a final dividend, if any, on the equity shares of the Company for the financial year ended 31 March 2023, subject to approval of the shareholders at the ensuing Annual General Meeting of the Company. Further, in accordance with the Company's Code of Conduct for Prohibition of Insider Trading, the Company has intimated its "designated persons" regarding the closure of the Trading Window for trading in the Company's equity shares from 01 April 2023 till the expiry of 48 hours from the date the said financial results are made public. The above information shall be uploaded on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> . Kindly take above intimation on your record and oblige.
28-Apr-23	Formal of the Initial Disclosure to be made by an entity identified as a Large Corporate - Annexure A
28-Apr-23	Formal of the Annual Disclosure to be made by an entity identified as a LC - Annexure B
4-May-23	The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nippon Life India Trustees Ltd
5-May-23	Outcome of board meeting held on 05 May 2023
5-May-23	Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and financial year ended 31 March 2023
5-May-23	The Board Recommended a Final Dividend of Rs. 2/- (20%) per equity share of Rs. 10/- each fully paid (subject to deduction of tax, if any) on the equity share capital of Rs. 22,16,50,620/- (2,21,65,06,200 equity shares of Rs. 10/- each) for the financial year 2022-23. This shall be paid subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company.
5-May-23	Based on the recommendation made by the Audit Committee, the Board of Directors of the Company recommended the re-appointment of M/s NDJ & Co., (Firm Registration No. 136345W), Chartered Accountants, Surat, as the Statutory Auditors of the Company for a second term of five (5) consecutive years from the conclusion of the ensuing 27th Annual General Meeting of the Company till the conclusion of the 32nd Annual General Meeting of the Company to be held in the year 2028, subject to the approval of the shareholders of the Company.
5-May-23	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed Investor Presentation for the quarter and financial year ended 31 March 2023. The above information shall be made available on the website of the Company at <a href="http://www.tatvachintan.com">www.tatvachintan.com</a> .

5-May-23	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Press Release on financial results of the Company for the quarter and financial year ended 31 March 2023. The above information shall be made available on the website of the Company at <a href="http://www.tatvacpharma.com">www.tatvacpharma.com</a> .
5-May-23	Disclosure of Related Party Transactions in the format specified under SEBI Circular bearing reference no. SEBI/HO/CFD/CMD1/CIR/P/2022/1662 dated 22 November 2021, for the half year ended 31 March 2023
5-May-23	Pursuant to Regulation 46(2)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we hereby inform the exchanges that the recording of the Earnings Call held on Friday, 05 May 2023 at 05:00 p.m. IST is available on the website of the Company. The recording can be accessed from the following link: <a href="https://www.tatvacpharma.com/content/uploads/2023/05/050520230505166602.mp3">https://www.tatvacpharma.com/content/uploads/2023/05/050520230505166602.mp3</a> . The above information is available on the website of the Company at <a href="http://www.tatvacpharma.com">www.tatvacpharma.com</a> .
6-May-23	Pursuant to regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we are enclosing herewith copies of newspaper publication of extract of financial results of the Company for the quarter and financial year ended 31 March 2023, published in Financial Express (English edition) and Vadodra Samachar (Gujarati edition) on 06 May 2023. The above information shall be made available on the website of the Company at <a href="http://www.tatvacpharma.com">www.tatvacpharma.com</a> .
9-May-23	Pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith statement of deviation(s) on variations in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended 31 March 2023 in the prescribed format. The same will be filed in XBRL mode separately. We confirm that, as at 31 March 2023, there has not been any deviation(s) on variations in the utilization of net proceeds of IPO as mentioned in the objects stated in the Prospectus dated 22 July 2021. Report issued by Monitoring agency report is being separately filed with the exchange. The above information shall be made available on the website of the Company at <a href="http://www.tatvacpharma.com">www.tatvacpharma.com</a> .
9-May-23	Pursuant to Regulation 32(8) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Monitoring Agency report of the Company for the quarter ended 31 March 2023, issued by ICI Bank Limited, appointed to monitor the utilization of proceeds of an Initial Public Offering (IPO) of the Company. The above information shall be made available on the website of the Company at <a href="http://www.tatvacpharma.com">www.tatvacpharma.com</a> .
10-May-23	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on 02 May 2023 post announcement of financial results of the Company for the quarter and financial year ended 31 March 2023. The above information shall be made available on Company's website at <a href="http://www.tatvacpharma.com">www.tatvacpharma.com</a> .
27-May-23	Submission of Annual Secretarial Compliance Report for the Financial Year ended 31 March 2023 (2022-23)
27-Jun-23	Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company will be hosting a plant visit at Dahaj SEZ Plant on Wednesday, 26 June 2023.
29-Jun-23	Tatva Chintan Pharma Chem Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
6-Jul-23	Tatva Chintan Pharma Chem Limited has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/07/2023, inter alia, to consider and approve Fund Raising and other business transactions, as applicable.
8-Jul-23	Compliance Certificate under Reg. 74 (b) of SEBI (DP) Regulations, 2018
11-Jul-23	Board Meeting Outcome for Outcome Of The Board Meeting Held On 11 July 2023: - raising further capital for an aggregate amount not exceeding Rs. 2,000 million approval of notice to seek requisite members approval by way of special resolution through Postal Ballot.
14-Jul-23	Notice of Postal Ballot under Section 113 of the Companies Act, 2023
15-Jul-23	Newspaper Advertisement - Dispatch of Notice of Postal Ballot
27-Jul-23	Tatva Chintan Pharma Chem Limited has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2023, inter alia, to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30 June 2023.
4-Aug-23	Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (SEBI Listing Regulations), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30 June 2023. The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 04 August 2023. Further, we enclose herewith Limited Review Report issued by M/s. ND & Co., Chartered Accountants. (Firm Registration No. 198249N), Statutory Auditors of the Company as required under Regulation 33 of SEBI Listing Regulations
4-Aug-23	Unaudited Financial Results (Standalone and Consolidated) Of The Company For the quarter ended on 30 June 2023
4-Aug-23	Investor Presentation for the quarter ended 30 June 2023
4-Aug-23	Press Release on Financial Results of the Company for the quarter ended 30 June 2023
4-Aug-23	Earnings Call Recording
4-Aug-23	Newspaper Publication of extract of Financial Results of the Company for the quarter ended 30 June 2023
9-Aug-23	Statement of Deviation / Variation in Utilization of funds raised through IPO for the quarter ended 30 June 2023
9-Aug-23	Monitoring Agency Report for Company for the quarter ended 30 June 2023
9-Aug-23	Transcript of the earnings call held on 04 August 2023 post announcement of financial results of the Company for the quarter ended 30 June 2023
11-Aug-23	Communication to Shareholders - Dividend for FY 2022-23 - Information on Tax Deduction at source (TDS) w/retrofitting tax on Dividend
14-Aug-23	Young Faculty and Scrutinizer's Report on the Postal Ballot.
19-Aug-23	Newspaper Advertisement - Disclosure under Regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI Listing Regulations")
24-Aug-23	Outcome of Meeting of "Fund Raising Committee" held on 24 August 2023
24-Aug-23	Closure of Trading Window
24-Aug-23	Intimation of Fund Raising Committee Meeting
26-Aug-23	Notice Of The 27th AGM Of The Members Of The Company Scheduled To Be Held On Friday, 22 September 2023 At 04:00 P.M. (IST) Through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM").
26-Aug-23	Tatva Chintan Pharma Chem Limited has informed BSE about Notice of Shareholders Meeting for Annual General Meeting
26-Aug-23	Pursuant to Regulation 34(1) of the SEBI Listing Regulations, please find enclosed herewith the Annual Report of the Company along with the Notice of the 27th Annual General Meeting (AGM) and other Statutory Reports for the Financial Year 2022-23. The same is also being sent through electronic mode to those members whose email addresses are registered with the Company Registrar and Share Transfer Agent/Depository Participants. Further, the 27th AGM of the Company will be held on Friday, 22 September 2023 at 04:00 p.m. (IST) through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM"). The Annual Report of the Company is also available on the website of the Company at <a href="http://www.tatvacpharma.com">www.tatvacpharma.com</a> .
26-Aug-23	Pursuant to Regulation 34(2)(v) of the SEBI Listing Regulations, we are submitting herewith the Business Responsibility and Sustainability Report ("BRSR") for FY 2022-23 which forms part of the Annual Report FY 2022-23. The BRSR is also available on the website of the Company at <a href="http://www.tatvacpharma.com">www.tatvacpharma.com</a> .
26-Aug-23	Intimation of Record date, Book Closure and Cut-off date pursuant to Regulation 42 and 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)
27-Aug-23	Newspaper Advertisement - Disclosure under Regulation 30, 44 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
29-Aug-23	Outcome of Meeting of Fund Raising Committee held on 29 August 2023
29-Aug-23	Qualified Institutions Placement - Fund Raising Committee Meeting
5-Sept-23	Intimation for Sale of Equity Shares of the Company in Open Market to Achieve Minimum Public Shareholding
7-Sept-23	Filing of Report under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 of Shrihari Ramesh Somani, member of Promoter/Promoter Group
7-Sept-23	Filing of Report under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 of Ajay Mansukhani Patel, member of Promoter/Promoter Group
7-Sept-23	Filing of Report under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 of Ajay Mansukhani Patel (HUF), member of Promoter/Promoter Group
7-Sept-23	Filing of Report under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 of Priti Ajay Patel, member of Promoter/Promoter Group
7-Sept-23	Filing of Report under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 of Darshana Nishikumar Shah, member of Promoter/Promoter Group
7-Sept-23	Enclosed is the report in the format prescribed in Form B of the circular bearing number SEBI/HO/REGD/CIR/P/2021/119 dated February 9, 2021 read with the circular bearing SEBI/HO/REGD/CIR/P/2022/240 dated March 29, 2022, issued by the Securities and Exchange Board of India. The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shrihari Ramesh Somani.
8-Sept-23	The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ajay Mansukhani Patel/HUF
8-Sept-23	The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Priti Ajay Patel
8-Sept-23	The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Darshana Nishikumar Shah
21-Sept-23	Intimation of Credit Rating
22-Sept-23	Summary of proceedings of the 27th Annual General Meeting held on Friday, 22 September 2023
23-Sept-23	Scrutinizer's Report / Voting Results of 27th Annual General Meeting of the Company held on Friday, 22 September 2023
26-Sept-23	Intimation of Closure of Trading Window
6-Oct-23	Certificate under Reg. 74 (b) of SEBI (DP) Regulations, 2018
20-Oct-23	Tatva Chintan Pharma Chem Limited has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2023, inter alia, to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30 September 2023. Further, in accordance with the Company's Code of Conduct for Prohibition of Insider Trading, the Company has intimated its "designated persons" regarding the closure of the Trading Window for trading in the Company's equity shares from 01 October 2023 till the expiry of 48 hours from the date the said financial results are made public. The above information is also being made available on the website of the Company at <a href="http://www.tatvacpharma.com">www.tatvacpharma.com</a> .
2-Nov-23	Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (SEBI Listing Regulations), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30 September 2023.
2-Nov-23	Unaudited Financial Results (Standalone and Consolidated) Of The Company For the Quarter And Half Year Ended On 30 September 2023
2-Nov-23	Investor Presentation for the Quarter and Half Year ended 30 September 2023.
2-Nov-23	Earnings Call Recording
3-Nov-23	Newspaper Publication of Extract of Financial Results of the Company for the Quarter and Half year ended 30 September 2023
7-Nov-23	Statement of Deviation / Variation in Utilization of funds raised through IPO for the quarter ended 30 September 2023
7-Nov-23	Statement of Deviation / Variation in Utilization of funds raised through QIP for the quarter ended 30 September 2023
7-Nov-23	Monitoring Agency Report for Qualified Institutions Placement ("QIP") for the quarter ended 30 September 2023
7-Nov-23	Transcript of the earnings call held on 02 November 2023 post announcement of financial results of the Company for the quarter and half year ended 30 September 2023
8-Nov-23	Monitoring Agency Report for Initial Public Offerings ("IPO") for the quarter ended 30 September 2023
10-Nov-23	Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") - Annual Maintenance Shutdown
26-Dec-23	Closure of Trading Window
26-Dec-23	Tatva Chintan Pharma Chem Limited-543321-Closure of Trading Window - XBRL
6-Jan-24	Compliance Certificate under Reg. 74 (b) of SEBI (DP) Regulations, 2018
11-Jan-24	Tatva Chintan Pharma Chem Limited has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/01/2024, inter alia, to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2023. Further, in accordance with the Company's Code of Conduct for Prohibition of Insider Trading, the Company has intimated its "designated persons" regarding the closure of the Trading Window for trading in the Company's equity shares from 01 January 2024 till the expiry of 48 hours from the date the said financial results are made public. The above information is also being made available on the website of the Company at <a href="http://www.tatvacpharma.com">www.tatvacpharma.com</a> .
11-Jan-24	TATVA CHINTAN PHARMA CHEM LIMITED has informed BSE about Board Meeting to be held on 20 Jan 2024 to consider financial statements for the period ended December 2023, Financial result
20-Jan-24	Board Meeting Outcome for Outcome Of The Board Meeting Held On 20.01.2024
20-Jan-24	Unaudited Financial Results (Standalone and Consolidated) Of The Company For the Quarter And Nine Months Ended On 31 December 2023
20-Jan-24	Announcement under Regulation 30 (LORD)- Investor Presentation
20-Jan-24	Earnings Call Recording
21-Jan-24	Newspaper Publication of Extract of Financial Results of the Company for the Quarter and Nine Months ended 31 December 2023.
23-Jan-24	Statement of Deviation / Variation in Utilization of funds raised through IPO for the quarter ended 31 December 2023.
23-Jan-24	Statement of Deviation / Variation in Utilization of funds raised through QIP for the quarter ended 31 December 2023.
23-Jan-24	Monitoring Agency Report for Initial Public Offerings ("IPO") for the quarter ended 31 December 2023.
23-Jan-24	Monitoring Agency Report for Qualified Institutions Placement ("QIP") for the quarter ended 31 December 2023.
24-Jan-24	Transcript of the earnings call held on 20 January 2024 post announcement of financial results of the Company for the quarter and nine months ended 31 December 2023
27-Jan-24	Intimation for Update in Website
26-Mar-24	Tatva Chintan Pharma Chem Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
26-Mar-24	Tatva Chintan Pharma Chem Limited has informed the Exchange about Closure of Trading Window
5-Apr-24	Tatva Chintan Pharma Chem Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
9-Apr-24	Ajay Mansukhani Patel has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
9-Apr-24	Darshana Nishikumar Shah has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

10-Apr-24	Shrihar Raskhal Soman has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
24-Apr-24	TATVA CHINTAN PHARMA CHEM LIMITED has informed the Exchange about Board Meeting to be held on 03-May-2024 to consider and approve the Yearly Audited Financial results of the Company for the period ended March 2024 and Dividend.
30-Apr-24	Tatva Chintan Pharma Chem Limited has informed the Exchange regarding information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Environmental Clearance.
3-May-24	Tatva Chintan Pharma Chem Limited has submitted to the Exchange, the financial results for the period ended March 31, 2024.
3-May-24	Tatva Chintan Pharma Chem Limited has informed the Exchange that Board of Directors at its meeting held on May 03, 2024, recommended Final Dividend of Rs. 2 per equity share.
3-May-24	Tatva Chintan Pharma Chem Limited has informed the Exchange about Dividend Updates
3-May-24	Tatva Chintan Pharma Chem Limited has informed the Exchange about Investor Presentation
3-May-24	TATVA CHINTAN PHARMA CHEM LIMITED has informed the Exchange regarding Outcome of Board Meeting held on 03-May-2024 for Dividend
3-May-24	Tatva Chintan Pharma Chem Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
3-May-24	Monitoring Agency Report for Initial Public Offering ("IPO") for the quarter ended 31 March 2024
3-May-24	Tatva Chintan Pharma Chem Limited has informed the Exchange about Link of Recording
4-May-24	Tatva Chintan Pharma Chem Limited has informed the Exchange about Copy of Newspaper Publication
7-May-24	Tatva Chintan Pharma Chem Limited has informed the Exchange about Transcript

**Notes:**

The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable. For further updates and information, please refer to the website of the Stock Exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and/or [www.nseindia.com](http://www.nseindia.com).

**Disclaimer:**

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by JM Financial Limited ("JM Financial") arising out of the SEBI Circular No. CIR/MIRSD/12012 dated January 10, 2012.

This information is gathered, inter-alia, from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and/or the National Stock Exchange of India Limited ("NSE" and together with the BSE, the "Stock Exchanges") from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

Nothing in this information is intended by JM Financial to be construed as legal, regulatory, accounting, tax or other advice. While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, JM Financial does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither JM Financial nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits, incidental or consequential damage, however arising, suffered or incurred by any person accessing and/ or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement. JM Financial does not undertake to revise the information presented herein except as required by applicable law or regulation.